Notizie e Video - INNATE PHARMA

Attualmente stai visualizzando tutte le notizie di borsa dello strumento finanziario INNATE PHARMA in tutti i mercati in tutte le lingue.

> Notizie Business Wire ha pubblicato una nuova notizia.

Innate Pharma organise une conférence téléphonique pour ses résultats financiers au troisième trimestre 2023 • • Business Wire • Azioni

Regulatory News: Innate Pharma SA (Euronext Paris : IPH ; Nasdaq : IPHA) (« Innate » ou la « Société ») annonce aujourd’hui qu’elle organise une conférence téléphonique le mardi 14 novembre 2023 à 14h00 CET / 8h00 ET afin de présenter ses résultats financiers et l’avancée de son portefeuille au troisième trimestre 2023. La conférence sera animée par : Mondher Mahjoubi, Président du Directoire Yannis Morel, Vice-président exécutif, Stratégie Produits & Business...

Grazie Grafico

> Notizie Business Wire ha pubblicato una nuova notizia.

Innate Pharma to Participate in Upcoming Investor Conference • • Business Wire • Azioni

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that members of its senior management team are scheduled to participate in the following upcoming conference: H.C. Wainwright Immune Cell Engager Virtual Conference Event Date: August 17 - virtual About Innate Pharma Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune...

Grazie Grafico

> Notizie Business Wire ha pubblicato una nuova notizia.

Prochain rendez-vous investisseurs d'Innate Pharma • • Business Wire • Azioni

Regulatory News: Innate Pharma SA (Euronext Paris : IPH ; Nasdaq : IPHA) (« Innate » ou la « Société ») annonce aujourd’hui que des membres de son équipe de direction seront présents à la conférence investisseurs suivante : H.C. Wainwright Immune Cell Engager Virtual Conference Date : 17 août 2023 - virtuel À propos d’Innate Pharma : Innate Pharma S.A. est une société de biotechnologies au stade clinique qui développe des traitements d’immunothérapies contre le cancer. Son...

Grazie Grafico

> Notizie Business Wire ha pubblicato una nuova notizia.

Innate Pharma to Participate in Upcoming Investor Conference • • Business Wire • Azioni

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that members of its senior management team are scheduled to participate in the following upcoming conference: H.C. Wainwright Immune Cell Engager Virtual Conference Event Date: August 17 - virtual About Innate Pharma Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness...

Grazie Grafico

> Notizie Business Wire ha pubblicato una nuova notizia.

Premier patient traité dans l'essai clinique de Phase 1/2 évaluant SAR’514 / IPH6401 dans le myélome multiple en rechute ou réfractaire • • Business Wire • Azioni

Regulatory News: Innate Pharma SA (Euronext Paris : IPH ; Nasdaq : IPHA) (« Innate » ou la « Société ») a annoncé aujourd’hui que le premier patient a été traité dans un essai clinique de Phase 1/2 ( NCT05839626 ) sponsorisé par Sanofi, évaluant SAR’514 / IPH6401 chez des patients présentant un myélome multiple en rechute/réfractaire et une amylose AL 1 en rechute/réfractaire. SAR’514 est un NK cell engager ciblant l’antigène de maturation des lymphocytes B (BCMA) qui...

Grazie Grafico

> Notizie Business Wire ha pubblicato una nuova notizia.

First Patient Dosed in SAR’514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma • • Business Wire • Azioni

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that the first patient was dosed in a Sanofi-sponsored Phase 1/2 clinical trial ( NCT05839626 ), evaluating SAR’514 / IPH6401 in relapsed/refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA) 1 . SAR’514 is a trifunctional anti-BCMA NKp46xCD16 NK cell engager, using Sanofi’s proprietary CROSSODILE ® multi-functional platform,...

Grazie Grafico

> Notizie Business Wire ha pubblicato una nuova notizia.

First Patient Dosed in SAR’514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma • • Business Wire • Azioni

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that the first patient was dosed in a Sanofi-sponsored Phase 1/2 clinical trial ( NCT05839626 ), evaluating SAR’514 / IPH6401 in relapsed/refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA) 1 . SAR’514 is a trifunctional anti-BCMA NKp46xCD16 NK cell engager, using Sanofi’s proprietary CROSSODILE ® multi-functional platform, which comprises the...

Grazie Grafico

> Notizie Business Wire ha pubblicato una nuova notizia.

Number of Shares and Voting Rights of Innate Pharma as of July 1, 2023 • • Business Wire • Azioni

Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) releases its total number of shares outstanding as well as its voting rights as at July 1, 2023: Total number of shares outstanding: 80,516,622 ordinary shares 6,514 Preferred...

Grazie Grafico

> Notizie Business Wire ha pubblicato una nuova notizia.

Number of Shares and Voting Rights of Innate Pharma as of July 1, 2023 • • Business Wire • Azioni

Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) releases its total number of shares outstanding as well as its voting rights as at July 1, 2023: Total number of shares outstanding: 80,516,622 ordinary shares 6,514 Preferred Shares 2016 7,581...

Grazie Grafico

> Notizie Business Wire ha pubblicato una nuova notizia.

Nouveau nombre d’actions et de droits de vote d’Innate Pharma au 1er juillet 2023 • • Business Wire • Azioni

Regulatory News: Conformément aux articles L. 233-8 II du Code de Commerce et 223-16 du règlement général de l’Autorité des marchés financiers (l’« AMF »), Innate Pharma SA (Euronext Paris : IPH ; Nasdaq : IPHA) (« Innate » ou la « Société ») publie le nombre d’actions composant son capital social ainsi que le nombre de droits de vote associés au 1 er juillet 2023 : Nombre d’actions composant le capital : 80 516 622 actions ordinaires 6 514 Actions de Préférence 2016 7...

Grazie Grafico

> Notizie Business Wire ha pubblicato una nuova notizia.

First Patient Dosed in Phase 2 MATISSE Trial of IPH5201 in Early Stage Lung Cancer • • Business Wire • Azioni

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced the first patient was dosed in MATISSE, a Phase 2 multicenter single-arm study ( NCT05742607 ), sponsored by Innate Pharma, evaluating neoadjuvant and adjuvant treatment with IPH5201, an anti-CD39 blocking monoclonal antibody, in combination with durvalumab (anti-PD-L1) and chemotherapy, in treatment-naïve patients with resectable early stage non-small cell lung cancer (NSCLC). The...

Grazie Grafico

> Notizie Business Wire ha pubblicato una nuova notizia.

Innate Pharma: First Patient Dosed in Phase 2 MATISSE Trial of IPH5201 in Early Stage Lung Cancer • • Business Wire • Azioni

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced the first patient was dosed in MATISSE, a Phase 2 multicenter single-arm study ( NCT05742607 ), sponsored by Innate Pharma, evaluating neoadjuvant and adjuvant treatment with IPH5201, an anti-CD39 blocking monoclonal antibody, in combination with durvalumab (anti-PD-L1) and chemotherapy, in treatment-naïve patients with resectable early stage non-small cell lung cancer...

Grazie Grafico

> Notizie Business Wire ha pubblicato una nuova notizia.

Innate Pharma : Traitement du premier patient dans l’essai de Phase 2 MATISSE évaluant IPH5201 dans les cancers du poumon au stade précoce • • Business Wire • Azioni

Regulatory News: Innate Pharma SA (Euronext Paris : IPH; Nasdaq : IPHA) (« Innate » ou la « Société ») a annoncé aujourd’hui que le premier patient a été traité dans l’essai de Phase 2 MATISSE ( NCT05742607 ) mené par Innate Pharma. MATISSE est une étude de Phase 2 multicentrique avec un seul bras de traitement évaluant IPH5201, un anticorps monoclonal anti-CD39, en traitement préopératoire et adjuvant en combinaison avec durvalumab (anti-PD-L1) et la chimiothérapie, chez des...

Grazie Grafico

> Notizie Business Wire ha pubblicato una nuova notizia.

Innate Pharma Highlights Increased Lacutamab Clinical Activity From Interim Results of Phase 2 TELLOMAK Study With Updated Olsen Criteria • • Business Wire • Azioni

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that interim efficacy results from the TELLOMAK Phase 2 study in advanced Mycosis Fungoides (MF) according to updated lymph node classification confirms clinical activity and favorable safety profile of lacutamab, an anti-KIR3DL2 antibody. The data were presented at the 17 th International Conference on Malignant Lymphoma, in Lugano, Switzerland. As of March 4, 2022, data...

Grazie Grafico

> Notizie Business Wire ha pubblicato una nuova notizia.

Innate Pharma Highlights Increased Lacutamab Clinical Activity From Interim Results of Phase 2 TELLOMAK Study With Updated Olsen Criteria • • Business Wire • Azioni

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that interim efficacy results from the TELLOMAK Phase 2 study in advanced Mycosis Fungoides (MF) according to updated lymph node classification confirms clinical activity and favorable safety profile of lacutamab, an anti-KIR3DL2 antibody. The data were presented at the 17 th International Conference on Malignant Lymphoma, in Lugano, Switzerland. As of March 4, 2022, data cutoff, patients...

Grazie Grafico

> Notizie Business Wire ha pubblicato una nuova notizia.

Innate Pharma présente une augmentation de l’activité clinique de lacutamab dans des résultats d’efficacité intermédiaires de l’essai de Phase 2 TELLOMAK actualisés selon les critères Olsen • • Business Wire • Azioni

Regulatory News: Innate Pharma SA (Euronext Paris : IPH; Nasdaq : IPHA) (« Innate » ou la « Société ») a annoncé aujourd’hui que des données d’efficacité de l’étude de Phase 2 TELLOMAK chez les patients présentant un mycosis fongoïde au stade avancé, mises à jour selon la classification actualisée des ganglions lymphatiques, confirment l’activité clinique et le profil de tolérance favorable de lacutamab, un anticorps anti-KIR3DL2. Les données ont été présentées à...

Grazie Grafico

> Notizie Business Wire ha pubblicato una nuova notizia.

Innate Pharma to Present Updated Interim Phase 2 Efficacy Results of Lacutamab in Mycosis Fungoides at the International Conference on Malignant Lymphoma • • Business Wire • Azioni

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that interim efficacy results from the TELLOMAK Phase 2 study of lacutamab in advanced Mycosis Fungoides will be presented at the 17 th International Conference on Malignant Lymphoma, being held in Lugano, June 13 – 17, 2023. Efficacy results will be presented according to updated lymph node classification. Presentation details Title: Lacutamab in patients with advanced...

Grazie Grafico

> Notizie Business Wire ha pubblicato una nuova notizia.

Innate Pharma présentera des données d’efficacité mises à jour de l’essai de Phase 2 avec lacutamab dans le mycosis fongoide au congrès de l’ICML • • Business Wire • Azioni

Regulatory News: Innate Pharma SA (Euronext Paris : IPH; Nasdaq : IPHA) (« Innate » ou la « Société ») a annoncé aujourd’hui que des données d’efficacité actualisées pour l’étude de Phase 2 TELLOMAK évaluant lacutamab chez les patients présentant un mycosis fongoïde avancé seront présentées à la 17 ème conférence internationale des lymphomes malins (International Conference on Malignant Lymphoma – ICML) qui se tiendra à Lugano, du 13 au 17 juin 2023. Les données...

Grazie Grafico

> Notizie Business Wire ha pubblicato una nuova notizia.

Innate Pharma to Present Updated Interim Phase 2 Efficacy Results of Lacutamab in Mycosis Fungoides at the International Conference on Malignant Lymphoma • • Business Wire • Azioni

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that interim efficacy results from the TELLOMAK Phase 2 study of lacutamab in advanced Mycosis Fungoides will be presented at the 17 th International Conference on Malignant Lymphoma, being held in Lugano, June 13 – 17, 2023. Efficacy results will be presented according to updated lymph node classification. Presentation details Title: Lacutamab in patients with advanced mycosis...

Grazie Grafico

> Notizie Business Wire ha pubblicato una nuova notizia.

Innate Pharma Highlights Proprietary Tetra-specific ANKET® NK Cell Engager IPH6501 at the EHA 2023 Congress • • Business Wire • Azioni

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that updated preclinical data on its IPH6501 tetra-specific ANKET ® ( A ntibody-based N atural K iller cell E ngager T herapeutics) are presented at the European Hematology Association (EHA) 2023 congress. IPH6501 is a first-in-class CD20-targeting tetra-specific ANKET ® that co-engages two activating receptors (NKp46 and CD16), the interleukin-2 receptor (without...

Grazie Grafico